Department of Gerontology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Department of Cardiothoracic Surgery, The First People's Hospital of Yunnan Province, Kunming, Yunnan, China.
Can J Cardiol. 2020 Nov;36(11):1782-1794. doi: 10.1016/j.cjca.2019.12.018. Epub 2019 Dec 28.
The most dangerous atherosclerotic plaques, referred to as "vulnerable," are most likely to trigger acute atherothrombotic events such as myocardial infarction (heart attack) and stroke. Our goal was to uncover the molecular drivers of vulnerable plaque formation.
To elucidate the functional gene modules that drive vulnerable plaque formation, we performed a weighted gene coexpression network analysis integrated with a protein-protein interaction network analysis in human atherosclerotic carotid samples, which identified the candidate gene granulocyte-macrophage colony-stimulating factor 2 (GM-CSF) receptor alpha subunit (CSF2RA). Follow-up in vitro experiments were performed to elucidate the regulatory relationship between CSF2RA and the microRNA miR-532-3p as well as modifiers of macrophagic miR-532-3p-CSF2RA axis expression. Microarray and quantitative reverse transcription polymerase chain reaction (qRT-PCR) studies elucidated the effect of statins on carotid miR-532-3p-CSF2RA axis expression in patients with carotid atherosclerotic disease. Apoe, Ldlr, and Csf2ra mutant Apoe mouse models of atherosclerosis were employed to assess the effects of agomiR-532-3p therapy in vivo.
The integrated weighted gene coexpression network analysis/protein-protein interaction network analysis revealed that the macrophagic GM-CSF receptor CSF2RA is significantly upregulated in macrophage-rich vulnerable plaques. Follow-up analysis identified the miR-532-3p-CSF2RA axis, as miR-532-3p downregulates CSF2RA via binding to CSF2RA's 3'UTR. Macrophagic miR-532-3p-CSF2RA dysregulation was enhanced via modified low-density lipoprotein or tumor necrosis factor α exposure in vitro. Moreover, this miR-532-3p-CSF2RA dysregulation was observed in human vulnerable plaques and Apoe mouse plaques, effects rescued by statin therapy. In vivo, agomiR-532-3p therapy suppressed murine plaque formation and promoted plaque stabilization in a Csf2ra-dependent manner.
Macrophagic miR-532-3p-CSF2RA axis dysregulation is a key driver in vulnerable plaque formation.
被称为“易损”的最危险的动脉粥样硬化斑块最有可能引发急性动脉血栓形成事件,如心肌梗死(心脏病发作)和中风。我们的目标是揭示易损斑块形成的分子驱动因素。
为了阐明驱动易损斑块形成的功能基因模块,我们对人动脉粥样硬化颈动脉样本进行了加权基因共表达网络分析与蛋白质-蛋白质相互作用网络分析的整合,确定了候选基因粒细胞-巨噬细胞集落刺激因子 2(GM-CSF)受体α亚基(CSF2RA)。随后进行了体外实验,以阐明 CSF2RA 与 microRNA miR-532-3p 之间的调控关系,以及调节巨噬细胞 miR-532-3p-CSF2RA 轴表达的修饰因子。微阵列和定量逆转录聚合酶链反应(qRT-PCR)研究阐明了他汀类药物对颈动脉粥样硬化疾病患者颈动脉 miR-532-3p-CSF2RA 轴表达的影响。采用载脂蛋白 E(Apoe)、低密度脂蛋白受体(Ldlr)和 CSF2RA 突变 Apoe 动脉粥样硬化小鼠模型评估体内 agomiR-532-3p 治疗的效果。
整合的加权基因共表达网络分析/蛋白质-蛋白质相互作用网络分析表明,富含巨噬细胞的易损斑块中巨噬细胞 GM-CSF 受体 CSF2RA 显著上调。后续分析确定了 miR-532-3p-CSF2RA 轴,因为 miR-532-3p 通过结合 CSF2RA 的 3'UTR 下调 CSF2RA。体外经修饰的低密度脂蛋白或肿瘤坏死因子 α 暴露可增强巨噬细胞 miR-532-3p-CSF2RA 的失调。此外,在人类易损斑块和 Apoe 小鼠斑块中观察到这种 miR-532-3p-CSF2RA 失调,他汀类药物治疗可挽救这种失调。体内,agomiR-532-3p 治疗以 CSF2ra 依赖的方式抑制小鼠斑块形成并促进斑块稳定。
巨噬细胞 miR-532-3p-CSF2RA 轴失调是易损斑块形成的关键驱动因素。